Agent Shunts Fluid Overload Via GI Tract
September 27, 2012|Internal Medicine
Author and Disclosure Information
AT THE ANNUAL MEETING OF THE HEART FAILURE SOCIETY OF AMERICA
Yet, the higher death rate with CLP "is certainly something to think about down the road," he acknowledged. "Obviously, as we proceed with clinical trials, we will try to decipher that and hope that it is a fluke and not an effect of the drug," he said.
Dr. Massie disclosed that he is a consultant to Sorbent Therapeutics, which sponsored the trial. Dr. Gottlieb disclosed no relevant conflicts of interest.
